| scholarly article | Q13442814 |
| P356 | DOI | 10.1126/SCITRANSLMED.AAA3230 |
| P8608 | Fatcat ID | release_3wkz36ssi5bgvfgfihih6vcb4y |
| P698 | PubMed publication ID | 25855493 |
| P5875 | ResearchGate publication ID | 274725802 |
| P50 | author | Christoph Daniel | Q47813115 |
| P2093 | author name string | Kerstin Amann | |
| Andreas Mackensen | |||
| Bettina Kempkes | |||
| Mario Fabri | |||
| Dimitrios Mougiakakos | |||
| Markus H Hoffmann | |||
| Frank Neumann | |||
| Fabian Beier | |||
| Armin Gerbitz | |||
| Maike Büttner | |||
| Heiko Bruns | |||
| Regina Jitschin | |||
| Anna Maurberger | |||
| Jörg T Bittenbring | |||
| Andreas D Hofmann | |||
| Shirin Pasemann | |||
| P2860 | cites work | The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know | Q22306208 |
| Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3 | Q28117302 | ||
| Cathelicidins, multifunctional peptides of the innate immunity | Q28205494 | ||
| Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3 | Q28258765 | ||
| Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response | Q28298985 | ||
| Tumour-educated macrophages promote tumour progression and metastasis | Q29614307 | ||
| CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans | Q29614348 | ||
| The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. | Q30486489 | ||
| Real-time attack on single Escherichia coli cells by the human antimicrobial peptide LL-37. | Q30499787 | ||
| Macrophages eliminate circulating tumor cells after monoclonal antibody therapy | Q30569758 | ||
| The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth | Q30933550 | ||
| Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. | Q33690078 | ||
| Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma | Q34144940 | ||
| Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. | Q34193968 | ||
| Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. | Q34659689 | ||
| Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group | Q34743615 | ||
| Mitochondrial metabolism and cancer | Q35008848 | ||
| Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages | Q35715983 | ||
| Function and therapeutic potential of host defence peptides. | Q36231828 | ||
| The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene | Q36366553 | ||
| The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy | Q36402637 | ||
| Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy | Q36414978 | ||
| Macrophages as mediators of tumor immunosurveillance | Q36823555 | ||
| NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors | Q36890816 | ||
| Divergence of macrophage phagocytic and antimicrobial programs in leprosy | Q37393776 | ||
| RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods | Q38420708 | ||
| Transformations in plasma membranes of cancerous cells and resulting consequences for cation insertion studied with molecular dynamics | Q39121077 | ||
| Resistance against natural killer cell cytotoxicity: analysis of mechanisms | Q40232562 | ||
| Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis | Q40339595 | ||
| Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma. | Q40455024 | ||
| Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages | Q40878586 | ||
| Control of cell growth by c-Myc in the absence of cell division | Q40919064 | ||
| Cytotoxicity and apoptosis mediated by two peptides of innate immunity | Q40999708 | ||
| Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. | Q41354177 | ||
| Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression | Q41750524 | ||
| CD40 ligand and interferon-γ induce an antimicrobial response against Mycobacterium tuberculosis in human monocytes | Q44743430 | ||
| Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). | Q46525283 | ||
| High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. | Q46845329 | ||
| A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. | Q46972244 | ||
| Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. | Q53085386 | ||
| Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. | Q53329309 | ||
| Vitamin D receptor gene polymorphisms and risk of non-Hodgkin's lymphoma | Q58419129 | ||
| P433 | issue | 282 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vitamin D | Q175621 |
| P304 | page(s) | 282ra47 | |
| P577 | publication date | 2015-04-01 | |
| P1433 | published in | Science Translational Medicine | Q1573955 |
| P1476 | title | Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma | |
| P478 | volume | 7 |
| Q41927566 | 1, 25(OH)2 D3 Induces Reactivation and Death of Kaposi's Sarcoma-Associated Herpesvirus of Primary Effusion Lymphoma cells |
| Q37406121 | Calcitriol stimulates gene expression of cathelicidin antimicrobial peptide in breast cancer cells with different phenotype |
| Q61810406 | Combination of lenalidomide and vitamin D enhances MOR202-mediated cytotoxicity of macrophages: It takes three to tango |
| Q51737061 | Health Risks of Hypovitaminosis D: A Review of New Molecular Insights. |
| Q88355804 | Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway |
| Q39267549 | Progress in tumor-associated macrophage (TAM)-targeted therapeutics |
| Q90077233 | Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma |
| Q39538318 | The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia. |
| Q90218153 | Vitamin D Deficiency and Janus kinase 2 V617F Mutation Status in Essential Thrombocythemia and Polycythemia Vera |
| Q38809673 | Vitamin D and patients with palliative cancer |
| Q47260924 | Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy. |
| Q30275725 | Vitamin D in hematological disorders and malignancies |
| Q57081044 | Vitamin D status contributes to the antimicrobial activity of macrophages against Mycobacterium leprae |
Search more.